Materias dentro de su búsqueda.
Mostrando 927,281 - 927,300 Resultados de 928,171 Para Buscar '"8½"', tiempo de consulta: 4.14s Limitar resultados
  1. 927281
    por Kremsner, Peter G, Ahuad Guerrero, Rodolfo Andrés, Arana-Arri, Eunate, Aroca Martinez, Gustavo Jose, Bonten, Marc, Chandler, Reynaldo, Corral, Gonzalo, De Block, Eddie Jan Louis, Ecker, Lucie, Gabor, Julian Justin, Garcia Lopez, Carlos Alberto, Gonzales, Lucy, Granados González, María Angélica, Gorini, Nestor, Grobusch, Martin P, Hrabar, Adrian D, Junker, Helga, Kimura, Alan, Lanata, Claudio F, Lehmann, Clara, Leroux-Roels, Isabel, Mann, Philipp, Martinez-Reséndez, Michel Fernando, Ochoa, Theresa J, Poy, Carlos Alberto, Reyes Fentanes, Maria Jose, Rivera Mejia, Luis Maria, Ruiz Herrera, Vida Veronica, Sáez-Llorens, Xavier, Schönborn-Kellenberger, Oliver, Schunk, Mirjam, Sierra Garcia, Alexandra, Vergara, Itziar, Verstraeten, Thomas, Vico, Marisa, Oostvogels, Lidia
    Publicado 2022
    “…In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
  2. 927282
    “…The percent of patients who were determined to have a complete response (CR), partial response (PR), clinical improvement (CI) was 63.5%, stable disease (SD) was 23.0%, patients with progression of disease 6.8% and 4 patients were indeterminate. Additionally, there was 1 death in the FURI study that was not related to fungal disease. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
  3. 927283
    “…This was despite more prior lines of treatment (median 2 [IQR 1-4] compared to 1 [IQR 1-1]; p<0.0001). 324 (58%) patients responded to the COVID-19 questions. 144/324 (44%) had undergone testing for COVID-19, with 11 (8%) returning a positive result; none after vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data
  4. 927284
    “…The incidence of COVID-19 infection for patients with AML/MDS-EB2 was 11.1% (90%CI: 7.8%-15.1%) (Table). A lower proportion of patients (n=6/91 6.6%) undergoing non-intensive treatment suffered COVID-19 as compared to those undergoing more intensive chemotherapy regimens (n=19/116, 16.4%). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
  5. 927285
    “…There was, however, an 18% statistically significant reduction (95% PI 9.9% - 25%) in in-person visit rates for White patients on orals during early pandemic months (March - May 2020) from a projected visit rate of 2.0 (95% PI 1.8 - 2.2) visits per patient per month to an actual visit rate of 1.61. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States
  6. 927286
    “…In NEWPT cohort, compared with their pre-COVID counterparts, patients in COVID period were more likely to receive monoclonal antibody (mAb) (14.4% vs 4.8%, p<.01, Figure B) and used IMID-based regimen as their first line of therapy (80.4% vs 74.3%, p<.01). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
  7. 927287
    “…Total tPA levels increased from a median 3.02 ng/ml (range 0.72 - 36.1 ng/ml) at baseline to 4.5 ng/ml (range 1.1-8.2 ng/ml) by day 4 in study subjects. Allowing for the small sample size, baseline PAI-1, tPA or D-Dimer levels did not impact response. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
  8. 927288
    “…We conducted a cross-sectional cohort study of pts with hematologic malignancies seen at Montefiore Medical Center between March 29, 2021 and July 8, 2021 who completed their vaccination series with 1 of the 3 FDA EUA COVID-19 vaccines, Moderna, Pfizer, or Johnson & Johnson (J&J). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort
  9. 927289
    “…For all diseases combined, early pandemic months (March - May 2020) saw an 18% (95% PI 8.9% - 25%) reduction in in-person visit rates averaged across OralTx and OutPtTx, with the projected rate being 1.5 (95% PI 1.3 - 1.6) visits per patient per month, compared to an actual rate of 1.2. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
  10. 927290
    “…Testing was performed at (or closest to) 4 and 8-weeks post-dose. Baseline nucleocapsid Ab results were available from previous screening in a subset of patients. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
  11. 927291
    “…In overweight and obese participants without T2DM: low‐carbohydrate weight‐reducing diets compared to balanced‐carbohydrate weight‐reducing diets (weight‐reducing phases only) probably result in little to no difference in change in body weight over three to 8.5 months (mean difference (MD) −1.07 kg, (95% confidence interval (CI) −1.55 to −0.59, I(2) = 51%, 3286 participants, 37 RCTs, moderate‐certainty evidence) and over one to two years (MD −0.93 kg, 95% CI −1.81 to −0.04, I(2) = 40%, 1805 participants, 14 RCTs, moderate‐certainty evidence); as well as change in DBP and LDL cholesterol over one to two years. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk
  12. 927292
    por Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L, Atako, Nafisah, Pugh, Cheryl, Buckner, Michelle, Chowdhury, Simon, Malik, Zafar, Russell, J Martin, Gilson, Clare, Rush, Hannah, Bowen, Jo, Lydon, Anna, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Tanguay, Jacob, Wagstaff, John, Das, Prantik, Gray, Emma, Alzoueb, Mymoona, Parikh, Omi, Robinson, Angus, Syndikus, Isabel, Wylie, James, Zarkar, Anjali, Thalmann, George, de Bono, Johann S, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, James, Nicholas D
    Publicado 2022
    “…Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8–10, and prostate-specific antigen [PSA] concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of <6 months, or a PSA concentration ≥20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0–2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
  13. 927293
    “…Patients with lupus nephritis are at risk of chronic kidney disease and it would be appropriate to have up-to-date immunization-status in case the patient needs renal transplant consideration in the future. 8. Patients should be able to continue study and in view of symptoms and the disruption due to illness, the hospital should offer support letters to schools/universities to enable flexibility with assignments and time extension. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    O07 Managing relapsing and refractory lupus nephritis in juvenile systemic lupus erythematosus: a case report
  14. 927294
    “…Of the 51,627 deaths, the majority (64.1%) were suicides, followed by homicides (25.1%), deaths of undetermined intent (8.7%), legal intervention deaths (1.4%) (i.e., deaths caused by law enforcement and other persons with legal authority to use deadly force acting in the line of duty, excluding legal executions), and unintentional firearm deaths (<1.0%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Surveillance for Violent Deaths — National Violent Death Reporting System, 42 States, the District of Columbia, and Puerto Rico, 2019
  15. 927295
    “…Serostatus data were not available for 20 (8%) of 262 participants. Among seronegative participants who received ChAdOx1 nCoV-19, anti-SARS-CoV-2 IgG and pseudoneutralising antibody titres at day 28 after the second dose were higher in participants aged 12–17 years with a longer interval between doses (geometric means of 73 371 arbitrary units [AU]/mL [95% CI 58 685–91 733] and 299 half-maximal inhibitory concentration [IC(50); 95% CI 230–390]) compared with those aged 12–17 years who received their vaccines 28 days apart (43 280 AU/mL [95% CI 35 852–52 246] and 150 IC(50) [95% CI 116–194]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
  16. 927296
    “…There was no evidence of a statistically significant difference in outcomes in the elective freeze group compared to the fresh embryo transfer group: healthy baby rate {20.3% (62/307) versus 24.4% (75/309); risk ratio (RR), 95% CI: 0.84, 0.62 to 1.15}; OHSS (3.6% versus 8.1%; RR, 99% CI: 0.44, 0.15 to 1.30); live birth rate (28.3% versus 34.3%; RR, 99% CI 0.83, 0.65 to 1.06); and miscarriage (14.3% versus 12.9%; RR, 99% CI: 1.09, 0.72 to 1.66). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze)
  17. 927297
    “…Le score FFS révisé moyen était de 1,3 lors de la pandémie, contre 0,8 auparavant (p = 0,02). La proportion de patients présentant au moins 1 item rénal, digestif ou cardiaque du FFS modifié était de 85 % depuis la pandémie, contre 56 % auparavant (p = 0,01). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    La pandémie de COVID-19 a-t-elle eu un impact délétère sur la prise en charge initiale des patients atteints de vascularites à ANCA ? Étude rétrospective interdisciplinaire au CHU de Nantes
  18. 927298
    “…Ivermectin may have little or no effect on clinical worsening, assessed by admission to hospital or death within 28 days (RR 1.09, 95% CI 0.20 to 6.02; 2 trials, 590 participants; low‐certainty evidence); on clinical improvement, assessed by the number of participants with all initial symptoms resolved up to 14 days (RR 0.90, 95% CI 0.60 to 1.36; 2 trials, 478 participants; low‐certainty evidence); on serious adverse events (RR 2.27, 95% CI 0.62 to 8.31; 5 trials, 1502 participants; low‐certainty evidence); on any adverse events during the trial period (RR 1.24, 95% CI 0.87 to 1.76; 5 trials, 1502 participants; low‐certainty evidence); and on viral clearance at day 7 compared to placebo (RR 1.01, 95% CI 0.69 to 1.48; 2 trials, 331 participants; low‐certainty evidence). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ivermectin for preventing and treating COVID‐19
  19. 927299
    por Li, Xiaofeng, Lu, Yun, Cheng, Xiantao
    Publicado 2022
    “…The experimental group participated in mindfulness cognitive behavior training for 8 weeks, 2 days a week, once a day, a total of 16 times. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    STUDY ON THE EFFECT OF MINDFULNESS COGNITIVE BEHAVIOR THERAPY IN THE TREATMENT OF ANXIETY DISORDER -- BASED ON THE PERSPECTIVE OF INDIVIDUAL REHABILITATION
  20. 927300
    “…Significantly greater proportions of pts receiving miri achieved IBDQ remission at W12 (18.1 [11.8, 24.4]) and W40 (28.5 [20.1, 37.0]) vs PBO (all evaluations and timepoints: p<0.001). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS
Herramientas de búsqueda: RSS